State
of New York
|
1-10113
|
11-0853640
|
(State
of Other Jurisdiction
|
(Commission
File Number)
|
(I.R.S.
Employer
|
of
Incorporation)
|
|
Identification
Number)
|
o |
Written
communications pursuant to Rule 425 under the Securities Act (17
CFR
230.425)
|
o |
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17CFR
240.14a-12)
|
o |
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act
(17CFR240.14d- 2(b))
|
o |
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act
(17CFR
240.13e- 4(c))
|
Exhibit Number |
Description
|
10.1 |
Joinder
and Amendment to Amended and Restated Voting Agreement dated November
9,
2005 between the Company, GCE Holdings, Care Capital, Essex and
Galen.
|
10.2 |
Loan
Agreement by and among Acura Pharmaceuticals, Inc. Essex Woodlands
Health
Venture V, L.P., Care Capital Investments II, L.P., Care Capital
Offshore
Investments II, L.P., Galen Partners III, L.P., Galen Partners
International III, L.P., Galen Employee Fund III, L.P., and
the Additional
Lenders that become a party thereto dated November 9, 2005.
|
10.3 |
Form
of Secured Promissory Note of Acura Pharmaceuticals,
Inc.
|
10.4 |
Subordination
Agreement by and among Essex
Woodlands Health Venture V, L.P., Care Capital Investments
II, L.P., Care
Capital Offshore Investments II, L.P., Galen Partners III,
L.P., Galen
Partners International III, L.P., and Galen Employee Fund III,
L.P., dated
November 9, 2005.
|
10.5 |
Company
General Security Agreement by and between Acura Pharmaceuticals,
Inc. and
Galen Partners III, L.P., as Agent, dated November 9,
2005
|
10.6 |
Guaranty
of Axiom Pharmaceutical Corporation, dated November 9,
2005
|
10.7 |
Guaranty
of Acura Pharmaceutical Technologies, Inc., dated November
9,
2005
|
10.8 |
Guarantors
Security Agreement by and among Axiom Pharmaceutical Corporation,
Acura
Pharmaceutical Technologies, Inc. and Galen Partners III, L.P.,
as Agent,
dated November 9, 2005
|
10.9 |
Stock
Pledge Agreement by and between Acura Pharmaceuticals, Inc.
and Galen
Partners III, L.P., as Agent, dated November 9,
2005
|
99.1 |
Press
Release dated November 10, 2005 Announcing Financial Results for
Third
Quarter 2005, Receipt of Interim Funding, Conversion of Preferred
Shares
and Update on OxyADFTM
Tablet Development and Cash Reserves
|
ACURA PHARMACEUTICALS, INC. | ||
|
|
|
By: | /s/ Peter A. Clemens | |
Peter A. Clemens |
||
Senior Vice President & Chief Financial Officer |
Exhibit Number |
Description
|
10.1 |
Joinder
and Amendment to Amended and Restated Voting Agreement dated November
9,
2005 between the Company, GCE Holdings, Care Capital, Essex and
Galen.
|
10.2 |
Loan
Agreement by and among Acura Pharmaceuticals, Inc. Essex Woodlands
Health
Venture V, L.P., Care Capital Investments II, L.P., Care Capital
Offshore
Investments II, L.P., Galen Partners III, L.P., Galen Partners
International III, L.P., Galen Employee Fund III, L.P., and
the Additional
Lenders that become a party thereto dated November 9, 2005.
|
10.3 |
Form
of Secured Promissory Note of Acura Pharmaceuticals,
Inc.
|
10.4 |
Subordination
Agreement by and among Essex
Woodlands Health Venture V, L.P., Care Capital Investments
II, L.P., Care
Capital Offshore Investments II, L.P., Galen Partners III,
L.P., Galen
Partners International III, L.P., and Galen Employee Fund III,
L.P., dated
November 9, 2005.
|
10.5 |
Company
General Security Agreement by and between Acura Pharmaceuticals,
Inc. and
Galen Partners III, L.P., as Agent, dated November 9,
2005
|
10.6 |
Guaranty
of Axiom Pharmaceutical Corporation, dated November 9,
2005
|
10.7 |
Guaranty
of Acura Pharmaceutical Technologies, Inc., dated November
9,
2005
|
10.8 |
Guarantors
Security Agreement by and among Axiom Pharmaceutical Corporation,
Acura
Pharmaceutical Technologies, Inc. and Galen Partners III, L.P.,
as Agent,
dated November 9, 2005
|
10.9 |
Stock
Pledge Agreement by and between Acura Pharmaceuticals, Inc.
and Galen
Partners III, L.P., as Agent, dated November 9,
2005
|
99.1 |
Press
Release dated November 10, 2005 Announcing Financial Results for
Third
Quarter 2005, Receipt of Interim Funding, Conversion of Preferred
Shares
and Update on OxyADFTM
Tablet Development and Cash Reserves
|